Search
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy. … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.
Gram-Positive Bacterial Infections
go.drugbank.com/conditions/DBCOND0029861Drugs: CefpiromeSynonyms: Disease Due to Gram-positive Bacteria, Infections due to Gram-positive pathogensIMCY-0141
go.drugbank.com/drugs/DB17019InvestigationalIMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesCinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalThe approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted … Panobinostat is marketed by Novartis under the brand name Farydak.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesChlormerodrin Hg-197
go.drugbank.com/drugs/DB09406ApprovedChlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.
Synonyms: Chlormerodrin Hg 197, Chlormerodrin Hg-197Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIn 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … [A7476,A7477] After the discovery of certain bacteria with the capacity to inactivate folate analogs such as methotrexate, carboxypeptidase G was identified and Carboxypeptidase G1 was first isolated
Nephrotic syndrome with lesion of minimal change glomerulonephritis
go.drugbank.com/conditions/DBCOND0089324Synonyms: Nephrotic syndrome due to minimal change disease, Nephrotic syndrome due to minimal change disease (disorder)